PUVA AND INTERFERON Α COMBINED THERAPY IN PATIENTS WITH MYCOSIS FUNGOIDES

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


The results of mycosis fungoides (MF) treatment using therapy that combines interferon α (IFNα) and PUVA-therapy are presented. We observed 16 patients with MF. The diagnoses were verified with histological, immunohictochemical methods and molecular analysis. The response to treatment was defined by the index of the modified assessment of the severity of skin lesions scale (mSWAT). In addition, the safety and tolerability of IFNα and PUVA-therapy were evaluated. In terms of the stage of the disease, patients were distributed as follows: IB-IB - 1 (6%), IIA - 3 (19%), IIB - 6 (38%), IIIA - 2 (12.5%), IIIB - 1 (6%), IVA - 2 (12.5%), IVB - 1 (6%). PUVA-therapy was performed four times a week with the initial dose of the irradiation 0.5-1.0 J/cm2. The course of therapy consisted of 40 ± 8 procedures. The total dose was 157 ± 45 J/cm2.IFNα was prescribed to patients (3 IU three times a week). The total dose was 96 ± 31 IU. After the therapy 12 (75%) patients with stage IB-IIIA, mSWAT index was reduced by 90-100%, which corresponded to complete clinical remission in the form of the disappearance of cutaneous manifestations and subjective sensations. 3 (19%) patients with stage IIIB-IVA had mSWAT index decreasing from 50 to 75%, i.e. partial remission was observed as decrease of the injury area and rash brightness, reduce scaling, itching. 1 (6%) patient with stage IVB had no effect of the therapy. Studies have shown that PUVA-therapy in combination with interferon α can be successfully used at patients with MF, regardless of the disease stages, however, more positive effect was in patients with stage IB-IIB MF.

Full Text

Restricted Access

About the authors

O. Yu Olisova

I.M. Setchenov First Moscow State Medical University

Moscow, 119991, Russian Federation

K. V Smirnov

I.M. Setchenov First Moscow State Medical University

Moscow, 119991, Russian Federation

Ekaterina Vladimirovna Grekova

I.M. Setchenov First Moscow State Medical University

Email: grekova_kate@mail.ru
Moscow, 119991, Russian Federation
graduate student of I.M. Setchenov First Moscow State Medical University, Moscow, 119991, Russian Federation.

References

  1. Жуков А.С., Белоусова И.Э., Самцов А.В. Иммунологические и молекулярно-генетические механизмы развития грибовидного микоза. Вестник дерматологии и венерологии. 2015; 4: 42-50
  2. Rodd A.L., Ververis K., Karagiannis T.C. Current and emerging therapeutics for cutaneous T-cell lymphoma: histone deacetylase inhibitors. Lymphoma. 2012; 2012: 1-10. http://dx.doi.org/10.1155/2012/290685
  3. Кунгуров Н.В., Кохан М.М., Куклин И.А., Римар О.Г. О совершенствовании оказания специализированной медицинской помощи больным злокачественными лимфомами кожи. Вестник дерматологии и венерологии. 2010; 3: 4-11.
  4. Лезвинская Е.М., Молочков В.А., Ларина Н.К. Заболеваемость злокачественными лимфомами кожи в Московской области и пути совершенствования лечебно-диагностической помощи больным. Российский журнал кожных и венерических болезней. 2000; 3(4): 12-7.
  5. Johnson V.E., Vonderheid E.C., Hess A.D., Eischen C.M., McGirt L.Y. Genetic markers associated with progression in early mycosis fungoides. J. Eur. Acad. Dermatol. Venerol. 2014; 28(11): 1431-5.
  6. Olsen E.A., Whittaker S., Kim Y.H., Duvic M., Prince H.M., Lessin S.R., Bernengo M.G. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J. Clin. Oncol. 2011; 29(18): 2592-8.
  7. Calonje E., Brenn T., Lazaar A., McKee P.H., eds. McKee’s pathology of the skin with clinical correlations. Amsterdam: Elsevier Saunders; 2012: 1311-420.
  8. Willerslev-Olsen A., Litvinov I.V., Fredholm S.M., Petersen D.L., Sibbesen D.L., Gniadecki N.A. IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides. Cell Cycle. 2014; 13(8): 1306-12.
  9. Bernier C., Nguyen J.M., Quereux G., Renault J.J., Bureau B., Dreno B. CD13 and TCR clone: markers of early mycosis fungoides. Acta Derm. Venereol. 2007; 87(2): 155-9.
  10. Братцева Е.В., Ротанов С.В. Современные подходы к диагностике грибовидного микоза. Вестник дерматологии и венерологии. 2010; 6: 16-22
  11. Yang H., Xu C., Tang Y., Wan C., Liu W., Wang L. The significance of multiplex PCR/heteroduplex analysis-based TCR gamma gene rearrangement combined with laser-capture microdissection in the diagnosis of early mycosis fungoides. J. Cutan. Pathol. 2012; 39(3): 337-46.
  12. Wysocka M., Benoit B.M., Newton S., Azzoni L., Montaner L.J., Rook A.H. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood. 2004; 104(13): 4142-9.
  13. Олисова О.Ю., Анпилогова Е.М. Современные методы диагностики и лечения Т-клеточной лимфомы кожи. Российский журнал кожных и венерических болезней. 2015; 18(5): 4-13
  14. Eichmuller S., Usener D., Thiel D., Schadendorf D. Tumor-specific antigens in cutaneous T-cell lymphoma. Int. J. Cancer. 2003; 104(4): 482-7

Statistics

Views

Abstract - 32

PDF (Russian) - 0

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2017 Olisova O.Y., Smirnov K.V., Grekova E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies